The IPO bandwagon continues to roll, and July is set to welcome one of its biggest offerings yet. Emcure Pharmaceuticals, a leading Indian pharma company with a global presence, is aiming to raise a significant ₹1,952.03 crore through its initial public offering. But before you jump on the IPO train, let’s take a closer look at the details and analyze the company’s strengths and weaknesses to help you make an informed decision.
Emcure Pharmaceuticals IPO details
| Offer Price | ₹960 – ₹1008 per share |
| Face Value | ₹10 per share |
| Opening Date | 3 July 2024 |
| Closing Date | 5 July 2024 |
| Total Issue Size (in Shares) | 19,365,346 |
| Total Issue Size (in ₹) | ₹1952.03 Cr |
| Issue Type | Book Built Issue IPO |
| Lot Size | 14 Shares |
Breaking Down the IPO
Emcure’s IPO is a book built issue, meaning the demand will determine the final price within a specified range. The issue is divided into two parts: a fresh issue of ₹800 crore to raise new capital and an offer for sale (OFS) of ₹1,152.03 crore by existing shareholders.
Investing in an IPO requires understanding the minimum lot size, which in this case is 14 shares. You can bid for multiples of 14 shares. The price band has been set between ₹960 and ₹1008 per share.
Who Gets What? Understanding IPO Allocation
Emcure has divided the IPO pie strategically. Here’s how the shares will be distributed:
- Qualified Institutional Buyers (QIBs): These large investors, like mutual funds and insurance companies, are allocated up to 50% of the shares.
- Non-Institutional Investors (NII): This category, including high-net-worth individuals, receives at least 15% of the shares.
- Retail Investors: Regular investors like you and me get a minimum of 35% of the offering.
- Employee Portion: A small portion (up to 108,900 shares) is reserved for company employees at a discounted price.
What’s the Money For? Understanding Objectives of the IPO
The company plans to utilize the net proceeds from the IPO primarily for two purposes:
- Debt Repayment: A portion of the funds will be used to repay or prepay outstanding loans, potentially improving the company’s financial health.
- General Corporate Purposes: The remaining funds will be used for various business needs, which could include expansion, research & development, or marketing initiatives.
P/E ratios of Peer companies
| Company | P/E Ratio |
| Dr. Reddy’s Laboratories Ltd | 17.93 |
| Cipla Ltd | 30.10 |
| Alkem Laboratories Ltd | 33.86 |
| Torrent Pharmaceutical Ltd | 57.74 |
| Mankind Pharma | 45.30 |
| Abbott India | 47.43 |
| J. B. Chemicals & Pharmaceutical Ltd | 50.49 |
Emcure Pharma IPO’s GMP: A Glimpse into Investor Sentiment
The grey market premium (GMP) for Emcure Pharma’s IPO is currently ₹264 per share. This indicates that some investors in the unofficial grey market are willing to pay ₹264 more than the IPO price. While not a guarantee of future performance, a high GMP can suggest strong investor interest. However, it’s crucial to remember that the grey market is unregulated, and the GMP is not always an accurate predictor of listing price.
Company Overview: A Leader in Niche Areas
Established in 1981, Emcure Pharmaceuticals has carved a niche for itself in the Indian pharma space. Here’s a snapshot of the company:
- Products: Develops, manufactures, and markets a broad range of pharmaceutical products (oral medications, injectables, biotherapeutics) across various therapeutic areas.
- Research & Development (R&D) Driven: Invests heavily in R&D for a differentiated product portfolio.
- Global Presence: Markets products in over 70 countries, including India, Europe, and Canada.
- Market Standing:
- Ranked 13th in domestic sales among Indian pharma companies (MAT September 2023).
- 4th in market share in its covered markets (MAT September 2023).
- Leading pharmaceutical company in gynaecology and HIV antiviral therapy (MAT September 2023).
Emcure Pharma’s Financial Health
Emcure’s financial performance paints a mixed picture. Revenue from operations grew a healthy 11% year-on-year in FY24, reaching ₹6,658 crore compared to ₹5,985 crore the previous year. However, profit after tax declined slightly by 6% YoY, dipping to ₹527 crore from ₹562 crore.
Notably, over half (50.84% and 53.16% for the six months ended September 30, 2023 and FY23 respectively) of the company’s revenue comes from the domestic market. This reliance is somewhat offset by strong domestic sales growth, exceeding the Indian pharmaceutical market average with a CAGR of 10.80% between September 2019 and September 2023.
Industry Outlook: Riding the Growth Wave?
The global pharmaceutical market is expected to witness consistent growth, with a projected CAGR of 5.0% – 5.5% between 2023 and 2028. This positive industry trend could potentially benefit Emcure’s future prospects.
- SWOT Analysis of Emcure Pharma
| STRENGTHS | WEAKNESSES |
| Diverse Product Portfolio: Emcure boasts a wide range of pharmaceutical products across various therapeutic areas, including niche segments like gynaecology and HIV antivirals. This diversification helps mitigate risk and provides consistent revenue streams. Strong Domestic Presence: Ranked 13th in domestic sales and with a CAGR exceeding the Indian pharma market average, Emcure has a well-established presence in India. This strong foundation can fuel future growth. Global Reach: Emcure’s presence in over 70 countries provides access to international markets and growth opportunities beyond India. R&D Focus: The company invests heavily in research and development, which can lead to innovative products and a stronger product pipeline. | Profitability Decline: Despite revenue growth, Emcure’s profit after tax has declined in the past year. This raises concerns about the company’s ability to convert sales into sustainable profits. Reliance on Domestic Market: While domestic sales are strong, over half of Emcure’s revenue comes from India. This makes the company vulnerable to fluctuations in the Indian market. Limited Product Uniqueness: While the product portfolio is diverse, some products might lack significant differentiation, making them susceptible to competition. High Valuation: Based on the grey market premium, the IPO price might be on the higher side, potentially impacting future returns. |
| OPPORTUNITIES | THREATS |
| Growing Global Market: The global pharmaceutical market is expected to experience significant growth in the coming years. By expanding its presence in international markets and developing innovative products, Emcure can capitalize on this trend. Rising Healthcare Expenditure: Increasing healthcare awareness and disposable income, particularly in emerging markets, can drive demand for Emcure’s products. Focus on Generics: The growing demand for affordable generic drugs presents an opportunity for Emcure to expand its market share in this segment. Government Initiatives: Supportive government policies promoting domestic pharmaceutical manufacturing can benefit Emcure. | Regulatory Changes: Stringent regulations and price controls in the pharmaceutical industry can impact profitability. Competition: The Indian pharma market is highly competitive, with both domestic and international players vying for market share. Currency Fluctuations: As Emcure operates globally, fluctuations in foreign exchange rates can affect its profitability. Patent Expirations: Expiry of patents on key drugs can lead to generic competition and erosion of market share. |
Conclusion:
Emcure Pharmaceuticals’ IPO presents an opportunity to invest in a pharmaceutical company with a well-established presence in India and a global footprint. The company boasts a diversified product portfolio across various therapeutic areas and prioritizes research and development. These factors can be viewed as positive attributes.
However, potential investors should also consider some contrasting aspects. The company’s profitability has dipped recently, and the IPO valuation based on grey market premiums might be on the higher side. Additionally, the competitive landscape of the pharmaceutical industry is a significant factor to weigh.
Remember, thorough research and a clear understanding of your risk tolerance are crucial before making any investment decisions. Consulting with a financial advisor is recommended to determine if the Emcure Pharma IPO aligns with your investment goals.
*Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This article is for education purposes only and shall not be considered as recommendation or investment advice by Research & Ranking. We will not be liable for any losses that may occur. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, membership of BASL, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors.
I’m Archana R. Chettiar, an experienced content creator with
an affinity for writing on personal finance and other financial content. I
love to write on equity investing, retirement, managing money, and more.